Discussing ASCVD Risk Score With Patients: Quantifying … · 2019. 9. 9. · calculating ASCVD...
Transcript of Discussing ASCVD Risk Score With Patients: Quantifying … · 2019. 9. 9. · calculating ASCVD...
1
Discussing ASCVD Risk Score With Patients: Quantifying Treatment Effect
Funded by the Agency for Healthcare Research and Quality (AHRQ) in the U.S. Department of Health & Human Services
East Asheville Family Health Care
Dr. James Early presenting
2
Heart Health NOWAdvancing Heart Health in NC Primary Care
Using the ASCVD risk score in daily practice:
- Dashboard not working
- Risk-based prescribing makes sense in the
context of better patient outcomes
- Improvement plan defined
* Rationale: Calculation of 10 year risk for patients without prior history
of CVD or event allows provider and patient to discuss risk reduction with
aspirin and/or statin therapy. Cardiovascular disease is the leading cause of
death in the US. Assessment of risk guides therapy to reduce morbidity and
mortality
3
Heart Health NOWUsing the ASCVD risk score in daily practice
Initial steps
- Train MA re: patient selection
- Create field for calculated scores created in EHR
- Office workflow developed
4
Heart Health NOWUsing the ASCVD risk score in daily practice
Actions Taken (1)
- For pre-appointment huddle, MA flags scheduled patients who
qualify by age parameters (40-79 years)
- If already has vascular disease diagnosis, flag removed
- Dr. Early’s computer has risk score site book marked; calculation
performed pre-visit (just prior) and printed out for patient viewing and
discussion
5
Heart Health NOWUsing the ASCVD risk score in daily practice
Actions Taken (2)
- Discussion and shared decision making ensues
- Statin and / or Aspirin prescribed
- MA enters risk score in EHR structured field
6
Heart Health NOWUsing the ASCVD risk score in daily practice
Results to Date
- 247 ASCVD calculations and discussions in first 4
months of plan
- 95 of these patients are now on Statins and 109
now on Aspirin (some were taking one or the other
at baseline)
7
Case 1
The patient is a 67y/o man retired from the insurance industry and a former body builder. He takes a blood pressure medication, aspirin, and vitamin supplements. BP is well controlled, total cholesterol is195 mg/dl and HDL cholesterol is 44 mg/dl. His ASCVD risk score was 19.3%. After reviewing these findings he agreed to continue his Lisinopril 5 mg and his 81mg aspirin but also agreed to start pravastatin 20 mg each evening for primary prevention to reduce this significant risk.
8
Case 2
The patient is a 61y/o women with a past medical history of MS and presents for routine f/u for persistent depression following the loss of her spouse 2 yrs ago. She is doing quite well with a slow intentional weight loss program and excellent BP control. She has also retired from her public government position. Her cholesterol measured at 252 mg/dl with an HDL of 72 mg/dl. Her calculated ASCVD risk score was 8.0% and she is a current smoker. She agreed to pursue smoking cessation and to reach her BMI target of 25. For immediate risk reduction we began atorvastatin 10mg to be taken along with Co Q 10 daily. She will continue Lexapro 20 mg as before.
9
Heart Health NOWUsing the ASCVD risk score in daily practice
Time effect on my visits?
Reaction and perceptions regarding the approach and impact after engaging over 200 folks?
10
Heart Health NOWAdvancing Heart Health in NC Primary Care
Conclusions
- With a system in place (huddles / MA training and participation),
calculating ASCVD risk scores is pretty easy.
- Time commitment before and during the visit is small
- Patients are impressed by the results and engage well in
risk prevention discussions
- It’s fun for the clinic team because interventions related to the risk
score are clearly impactful
11
How Impactful Can HHN Interventions Be?
12
Some ASCVD Risk Score Facts
The score does not apply to people who already have vascular disease
It’s preferred to Framingham because it includes stroke
Overestimates the risk for highest end of SES and for people of Asian decent
Underestimates the risk for those with inflammatory conditions, e.g Rheumatoid Arthritis, HIV
13
Some ASCVD Risk Score Facts
Simply repeating the risk score after treatment does not provide accurate results for new risk status!!!!
Only establishes baseline risk.
So how do patients know how much treatment will help?
14
Lloyd-Jones et al. J Am Coll Cardiol. 2017 Mar 28;69(12):1617-1636
Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool
15
How Does Each ABCS Intervention Help?
16
Hypertension
Achieving blood pressure control – average relative risk reduction of 25%
17
Aspirin
Adding an 81mg aspirin leads to a 10% relative risk reduction
18
Statins
Statin treatment produces a relative risk reduction of 25%
14% reduction in all-cause mortality
Diet and exercise counseling have independent effects on CVD risk
19
Smoking Cessation
Greatest potential benefit but takes time!
20
Time Since Tobacco Cessation
ASCVD Relative Risk Reduction
1 year 15%
2 years 25%
3 years 40%
4 years 50%
Other Important Principles
Treatment effects (relative risk reduction) are multiplicative but cannot achieve improvements better than the age-based minimum
The absolute risk reduction is greater when the baseline risk is greater.
(For example, if baseline risk score is 8% then
starting a statin will reduce the risk score by 25% to
6%, a 2% absolute risk reduction. If baseline = 20%
the post-statin risk score becomes 15%, a 5%
absolute risk reduction) 21
Dr. Early’s - Case 1
The patient is a 67y/o man retired from the insurance industry and a former body builder. He takes a blood pressure medication, aspirin, and vitamin supplements. BP is well controlled, total cholesterol is195 mg/dl and HDL cholesterol is 44 mg/dl. His ASCVD risk score was 19.3%. After reviewing these findings he agreed to continue his Lisinopril 5 mg and his 81mg aspirin but also agreed to start pravastatin 20 mg each evening for primary prevention to reduce this significant risk.
Adding pravastatin reduces ASCVD risk score to 15.5%
Having the aspirin on board decreases to 14%
If uncontrolled HTN at baseline, gets controlled then score falls to 11.2%*
22* Nearly halve 10 year mortality risk
Your Turn
H.R. is a 58 y/o white male who is here for a BP check. He has had several readings of 180/104 at the pharmacy. His BP is similar on your exam. His cholesterol is 230 with an HDL of 32. He smokes a pack of cigs per day. Hgb A1c is 5.5. Hates to take medicine!
? Baseline risk score
? How would you address treatment options
23
Your Turn
H.R. is a 58 y/o white male who is here for a BP check. He has had several readings of 180/104 at the pharmacy. His BP is similar on your exam. His cholesterol is 230 with an HDL of 32. He smokes a pack of cigs per day. Hgb A1c is 5.5. Hates to take medicine!
? Baseline risk score 32%
? How would you address treatment options
- BP controlled – 24%
- Then statin – 18%
- Add aspirin – 16.2%
- Smoking cessation can drop risk to 8% (4 years) 24
Conclusions
The higher a patient is at risk the more he or she benefits from cardiovascular risk reduction therapies
As Dr. Early described, just showing a patient his / her 10 year risk of heart attack, stroke, or death can motivate acceptance of new medical therapy
Adding the potential benefit and sharing in a step wise manner, may motivate at risk patients even further.
25